Previously, based on the concept of bifunctional radiopharmaceuticals, we developed a
highly stable 186Re-mercaptoacetylglycylglycylglycine (MAG3) complex–conjugated …

Rhenium-186-1-hydroxyethylidene-1, 1-diphosphonate (186Re-HEDP) has been used for
the palliation of metastatic bone pain. Delayed blood clearance and high gastric uptake of …

To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative …

Purpose We have developed a 186 Re-mercaptoacetylglycylglycylglycine complex-
conjugated bisphosphonate (186 Re-MAG3-HBP) for the treatment of painful bone …

Abstract Objective Rhenium-188-hydroxyethylidene diphosphonate (188 Re-HEDP) as a
first generation bisphosphonate has been widely used for bone seeking …

INTRODUCTION: Based on the concept of bifunctional radiopharmaceuticals, we have
previously developed 186Re-complex-conjugated bisphosphonate analogs for palliation of …

INTRODUCTION: The preferable pharmacokinetics of rhenium-186 (186Re)-
monoaminemonoamidedithiol-conjugated or 186Re-mercaptoacetyltriglycine-conjugated …

To develop a radiopharmaceutical for the palliation of painful bone metastases based on the
concept of bifunctional radiopharmaceuticals, we designed a bisphosphonate derivative …

188 Rhenium-hydroxyethylidene-1, 1-diphosphonate (188 Re-HEDP) is a clinically
established radiopharmaceutical for bone pain palliation of patients with metastatic bone …

Two new bisphosphonates have been examined for their ability to bind 188Re and deliver it
selectively to bone. The bisphosphonates are prototype compounds with potential to deliver …